Editas Medicine Announces First Quarter 2017 Results and Update
15 mai 2017 16h01 HE
|
Editas Medicine
Entered strategic R&D alliance with ophthalmology leader Allergan to develop and commercialize ground-breaking medicines for patients with serious eye diseases Completed successful follow-on...
Editas Medicine to Present at Investor Conferences in May
08 mai 2017 16h01 HE
|
Editas Medicine
CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...
Editas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results
08 mai 2017 16h01 HE
|
Editas Medicine
CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday,...
Editas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update
07 mars 2017 16h01 HE
|
Editas Medicine
Recent, highly favorable U.S. Patent and Trademark Office decision affirms and upholds fundamental CRISPR/Cas9 issued patents Extended CRISPR technology leadership with addition of novel and...
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2016 Corporate Update and Results
28 févr. 2017 16h01 HE
|
Editas Medicine
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday,...
Editas Medicine to Present at Investor Conferences in March
27 févr. 2017 16h01 HE
|
Editas Medicine
CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...
Editas Medicine to Present at Upcoming February Investor Conferences
10 févr. 2017 16h01 HE
|
Editas Medicine
CAMBRIDGE, Mass., Feb. 10, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will present a company overview at two...
Editas Medicine to Present at the 35th Annual J.P. Morgan Healthcare Conference
04 janv. 2017 08h01 HE
|
Editas Medicine
CAMBRIDGE, Mass., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a...
Editas Medicine to Present at the Stifel Healthcare Conference 2016
09 nov. 2016 08h00 HE
|
Editas Medicine
CAMBRIDGE, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview at the Stifel...
Editas Medicine Announces Third Quarter 2016 Results and Update
07 nov. 2016 16h01 HE
|
Editas Medicine
Further strengthened leadership team with appointments of Charles Albright, Ph.D., as Chief Scientific Officer, and Gerald Cox, M.D., Ph.D., as Chief Medical Officer CAMBRIDGE, Mass., Nov. 07,...